|
Epigenetics
22nd September 2010 |
|
| Programme: | |
| 09.00 | Arrival, Registration and Coffee |
| Session 1 - Introducing Epigenetics - Chair – Richard Armer, Lectus Therapeutics | |
| 10.00 |
Karl Nightingale, Birmingham Medical
School Fundamental Biology of Epigenetics |
| 10.45 |
Nessa Carey, Cellcentric, UK Therapeutic Opportunities in Epigenetics |
| 11.30 |
Gerard Drewes, Cellzome AG, Germany Chemical Proteomics Tools for Drug Discovery in Epigenetics |
| 12.15 | Lunch |
|
Session 2 - Marketed Medicines from Epigenetics - Chair – Ruth Lock, Novartis |
|
| 13.30 |
Thomas Miller, Merck, USA Zolinza (Vorinostat, SAHA) – Case History |
| 14.15 |
Pierre Wijermans, Haga Hospital,
Netherlands Dacogen (Decitabine) – Case History |
| 15.00 | Tea |
| Session 3 - Epigenetics – the Next Wave - Chair – Phil Jeffrey, GSK | |
| 15.30 |
Stephen Shuttleworth, Karus, UK |
| 16.15 |
Jason Witherington, GSK, UK Bromodomains – a tractable Epigenetic target for drug discovery |
| 17.00 | Close |
| Home / Meetings / Membership / Student Bursaries / Administration / History of the SMR / SMR Award / Archive Material / Links / Contact Us |